Dr. Reddy’s Laboratories to acquire Mayne Pharma’s US retail generics portfolio
Dr. Reddy's Laboratories has agreed to acquire the US generic prescription product portfolio of Mayne Pharma Group, an Australian pharma company, in a deal worth ... Read More
Dr. Reddy’s Labs signs deal worth up to $150m to sell E7777 rights to Citius
Dr. Reddy's Laboratories (Dr. Reddy's Labs) has agreed to divest its rights to E7777, an engineered IL-2-diphtheria toxin fusion protein, and certain related assets to ... Read More
Dr. Reddy’s Labs to sell certain rights for ELYXYB to BioDelivery Sciences
Dr. Reddy's Laboratories (Dr. Reddy's Labs) has agreed to divest its US and Canada rights for migraine drug — ELYXYB (celecoxib oral solution) 25 mg/ml, ... Read More
Dr Reddy’s Laboratories to acquire generic injectable products in the US
Dr Reddy’s Laboratories has agreed to acquire a portfolio of 42 approved, non-marketed abbreviated new drug applications (ANDAs) in the US, which includes more than ... Read More